couter

NBTXNanobiotix S.A.

Health CarePharmaceuticals
Oct 15, 2026 — NANORAY-312 Phase 3 Interim Efficacy Readout
Chart by TradingView

The schedule

  • Thu15Oct

    Pivotal Phase 3 data for NBTXR3 in head and neck squamous cell carcinoma.

  • Thu12Nov

    Quarterly financial results focusing on remaining cash runway and potential dilutive financing.

  • Wed20Jan

    Anticipated alignment with the FDA on the regulatory approval pathway or required trial modifications.

  • Tue9Feb

    Year-end financial results detailing forward R&D budget and commercial preparedness.